Revenue continued to climb for MannKind’s inhalable insulin product Afrezza, gaining 35 percent in the fourth quarter to $7.8 million, but net loss rose 46 percent to $14 million during the period. Overall in 2019, the Westlake Village biotech grew sales of Afrezza 46 percent to $25.6 million, slimming net losses by 40 percent to…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
